期刊文献+

心力衰竭患者血浆N端脑钠肽前体水平及临床意义(附65例分析) 被引量:1

下载PDF
导出
摘要 目的观察N端脑钠肽前体(NT-proBNP)在心力衰竭患者血浆中的表达并探讨其临床意义。方法选取我院收治的心力衰竭患者65例为心衰组,同期健康体检者40例为对照组。分别检测两组受试者的血浆NT-proBNP水平及左室射血分数(LVEF)及左室舒张末期内径(LVEDD)等心功能指标,比较两组差异及随访结果。结果心衰组血浆NTproBNP水平、LVEDD均高于对照组,LVEF低于对照组,组间比较,差异有统计学意义(P<0.01);血浆NT-proBNP水平与LVEF呈相关(r=-0.791,P<0.01),与LVEDD呈正相关(r=0.680,P<0.01);至随访结束,心衰组的死亡率及心血管事件发生率均高于对照组,差异有统计学意义(P<0.05)。结论 NT-proBNP在心力衰竭患者血浆中特异性高表达,并与患者的LVEF、LVEDD密切相关,可作为临床诊断或判断预后的参考指标。
作者 陈瑞达
出处 《福建医药杂志》 CAS 2015年第6期108-110,共3页 Fujian Medical Journal
  • 相关文献

参考文献7

  • 1Ndumele C E, Matsushita K, Sang Y, et al. Abstract P021: NT-proBNP Predicts Incident Heart Failure Among Individuals in All BMI Categories [J]. Circulation, 2014, 129 (Suppl1) : 21.
  • 2Palazzuoli A, Gallotta M, Quatrini I, et al. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure[J]. Vascular health and risk management, 2010, 6 (1): 411-418.
  • 3张健,邹长虹.欧美心力衰竭指南更新亮点初析[J].中国循环杂志,2013,28(7):481-482. 被引量:9
  • 4McMurray J J, Adamopoulos S, Anker S D, et al. ESC Guide- lines for the diagnosis and treatment of acute and chronic heart failure 2012 [J]. European journal of heart failure, 2012, 14 (8) : 803-869.
  • 5Dini F L, Conti U, Fontanive P, et al. Prognostic Value of N- Terminal Pro-Type-B Natriuretic Peptide and Doppler Left Ven- tricular Diastolic Variables in Patients With Chronic Systolic Heart Failure Stabilized by Therapy [J].The American journal of cardiology, 2008, 102 (4): 463-468.
  • 6Boerrigter G, Costello-Boerrigter L C, Burnett-Jr J C. Natri- uretic peptides in the diagnosis and management of chronic heart failure [J]. Heart failure clinics, 2009, 5 (4): 501-514.
  • 7汪芳,李卫,黄洁,王莉,边文彦,庞会敏,王洋,顼志敏,李一石.血浆N末端原脑利钠肽水平对慢性心力衰竭患者长期预后的预测价值[J].中华心血管病杂志,2006,34(1):28-32. 被引量:83

二级参考文献11

  • 1Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department(PRIDE) study. Am J Cardiol.2005 .95 :948-954.
  • 2Pemberton C J, Yandle TG, Radenmker MT, et al. Amino-terminal proBNP in ovine plasma: evidence for enhanced secretion in response to cardiac overload. Am J Physiol, 1998, 275:1200-1208.
  • 3Mancia G. Neurohumoral activation in congestive heart failure. Am Heart J, 1990,120:1532-1537.
  • 4Yeo KT, Wu AH, Apple FS, et aL Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta, 2003, 338: 107-115.
  • 5Tsutsmoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide levels as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Eur Heart J, 1999, 20:1799-1807.
  • 6Omland T, Aakvaag A, Bonarjee WS,et aL Plasma brain natriuretic peptide as an indicator of left ventricular systolic dysfunction and long-term survival after acute myocardial infarction: comparion with plasma atrial natriuretic peptide and N-terminal proatria natriuretic peptide. Circulation, 1996,93 : 1963-1969.
  • 7Mc Donagh T, Cunningham AD, Morrison CE, et al. Left ventricular dysfunction, natriuretic poptide, and mortality in an urban population. Heart,2001,86:21-26.
  • 8Squire IB, O'Brien RJ, Demme B, et al. N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clin Sci,2004, 107:309-316.
  • 9Richard MA, Nicholls GM, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin : new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation, 1998, 97 : 1921-1929.
  • 10Bazzino O, Fuselli JJ, Botto F, et al. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J, 2004, 25:859-866.

共引文献90

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部